Topic

Articles

FDA has approved AstraZeneca’s Saphnelo, a type I interferon receptor antibody for treating systemic lupus erythematosus.

FDA Approves AstraZeneca’s Lupus mAb, Saphnelo

Byondis and Glycotope have formed an agreement to discover and develop antibodies that target specific glyco-epitopes.

Byondis and Glycotope Partner on Discovery and Development of Glyco-Epitope-Targeting Antibodies

Amgen’s Aimovig has become the first and only approved treatment in Japan for treating migraine attacks in adults by blocking the CGRP-R.

Amgen’s Aimovig Approved in Japan for Treating Migraine

FDA has granted breakthrough therapy designation to donanemab, Eli Lilly and Co.’s investigational antibody treatment for Alzheimer’s disease.

Lilly's Investigational Alzheimer's Therapeutic Gets Breakthrough Therapy Designation

Projects led by collaborating researchers from both Sanofi and Stanford Medicine will focus on autoimmune diseases and inflammatory conditions.

Sanofi Forms Three-Year Immunology Research Collaboration with Stanford Medicine

Eli Lilly and Company has partnered with leading diabetes tech firms to offer app compatibility with insulin smart pens to streamline diabetes management with automated data collection.

Lilly Forms Pact with Diabetes Tech Companies to Integrate Connected Insulin Pen Solutions

The European Commission has approved an additional indication for Roche’s Tecentriq (atezolizumab) as a first-line monotherapy treatment for metastatic non-small cell lung cancer.

EC Approves Additional Indication for Roche’s Tecentriq in Lung Cancer Treatment

Feliza Mirasol is the science editor for 

FDA’s newly proposed draft guidance will support IND filings of antisense oligonucleotides, a new class of drugs.

Growing Pipeline of Antisense Oligonucleotides Prompts Guidance

A growing pipeline of gene therapy candidates aimed at treating neurodegenerative diseases has prompted new guidance.

Gene Therapies Target Neurodegenerative Diseases

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Therapeutic Specific Areas